Ryvu Therapeutics S.A. (RVU.WA)
PLN 32.85
(1.39%)
PLN 32.85
(1.39%)
| Year | Eps | Eps Growth |
|---|---|---|
| 2023 | -4.02 PLN | 12.04% |
| 2022 | -4.57 PLN | -8.29% |
| 2021 | -4.22 PLN | -123.28% |
| 2020 | -1.89 PLN | 16.0% |
| 2019 | -2.25 PLN | -32508.7% |
| 2018 | -0.01 PLN | -101.44% |
| 2017 | 0.48 PLN | 140.0% |
| 2016 | 0.20 PLN | -58.33% |
| 2015 | 0.48 PLN | -14.29% |
| 2014 | 0.56 PLN | 343.48% |
| 2013 | -0.23 PLN | 62.3% |
| 2012 | -0.61 PLN | -45.24% |
| 2011 | -0.42 PLN | -121.05% |
| 2010 | -0.19 PLN | 0.0% |
| Year | Eps | Eps Growth |
|---|---|---|
| 2024 Q1 | -0.84 PLN | 30.0% |
| 2024 Q2 | -1.40 PLN | -66.67% |
| 2023 Q2 | -1.23 PLN | -55.7% |
| 2023 Q1 | -0.79 PLN | -71.74% |
| 2023 FY | - PLN | 12.04% |
| 2023 Q4 | -1.20 PLN | -51.9% |
| 2023 Q3 | -0.79 PLN | 35.77% |
| 2022 Q3 | -0.64 PLN | 59.75% |
| 2022 Q1 | -1.45 PLN | -57.61% |
| 2022 Q2 | -1.59 PLN | -9.66% |
| 2022 FY | - PLN | -8.29% |
| 2022 Q4 | -0.46 PLN | 28.13% |
| 2021 Q4 | -0.92 PLN | 25.81% |
| 2021 Q1 | -0.74 PLN | -13.85% |
| 2021 FY | - PLN | -123.28% |
| 2021 Q2 | -1.32 PLN | -78.38% |
| 2021 Q3 | -1.24 PLN | 6.06% |
| 2020 Q4 | -0.65 PLN | 10.96% |
| 2020 FY | - PLN | 16.0% |
| 2020 Q1 | -0.27 PLN | 54.24% |
| 2020 Q2 | -0.27 PLN | 0.0% |
| 2020 Q3 | -0.73 PLN | -170.37% |
| 2019 Q1 | -0.48 PLN | 40.74% |
| 2019 Q4 | -0.59 PLN | -136.0% |
| 2019 FY | - PLN | -32508.7% |
| 2019 Q3 | -0.25 PLN | 55.36% |
| 2019 Q2 | -0.56 PLN | -16.67% |
| 2018 Q3 | -0.19 PLN | 24.0% |
| 2018 Q4 | -0.81 PLN | -326.32% |
| 2018 FY | - PLN | -101.44% |
| 2018 Q2 | -0.25 PLN | -120.16% |
| 2018 Q1 | 1.24 PLN | 875.0% |
| 2017 FY | - PLN | 140.0% |
| 2017 Q3 | 0.06 PLN | -72.76% |
| 2017 Q1 | 39.50 PLN | 14529.63% |
| 2017 Q2 | 0.21 PLN | -99.47% |
| 2017 Q4 | -0.16 PLN | -379.72% |
| 2016 Q1 | -0.18 PLN | -280.0% |
| 2016 FY | - PLN | -58.33% |
| 2016 Q4 | 0.27 PLN | 42.11% |
| 2016 Q3 | 0.19 PLN | 321.19% |
| 2016 Q2 | -0.09 PLN | 52.28% |
| 2015 Q4 | 0.10 PLN | -16.67% |
| 2015 Q3 | 0.12 PLN | -25.0% |
| 2015 Q2 | 0.16 PLN | -98.35% |
| 2015 Q1 | 9.70 PLN | 4519.05% |
| 2015 FY | - PLN | -14.29% |
| 2014 Q1 | 0.06 PLN | 79.94% |
| 2014 Q4 | 0.21 PLN | 31.25% |
| 2014 Q3 | 0.16 PLN | 14.29% |
| 2014 Q2 | 0.14 PLN | 151.8% |
| 2014 FY | - PLN | 343.48% |
| 2013 Q4 | 0.03 PLN | 142.74% |
| 2013 FY | - PLN | 62.3% |
| 2013 Q1 | -0.10 PLN | 49.89% |
| 2013 Q2 | -0.09 PLN | 3.99% |
| 2013 Q3 | -0.07 PLN | 20.9% |
| 2012 Q3 | -0.09 PLN | 50.11% |
| 2012 FY | - PLN | -45.24% |
| 2012 Q2 | -0.18 PLN | -12.5% |
| 2012 Q1 | -0.16 PLN | 0.0% |
| 2012 Q4 | -0.19 PLN | -111.58% |
| 2011 FY | - PLN | -121.05% |
| 2010 FY | - PLN | 0.0% |
| Name | Eps | Eps Difference |
|---|---|---|
| Bioceltix S.A. | -3.49 PLN | -15.186% |
| BIOTON S.A. | 0.03 PLN | 15269.811% |
| Captor Therapeutics Spolka Akcyjna | -15.19 PLN | 73.535% |
| Mabion S.A. | 2.55 PLN | 257.647% |
| Molecure S.A. | -1.09 PLN | -268.807% |
| NanoGroup S.A. | -0.39 PLN | -930.769% |
| Pharmena S.A. | 2.60 PLN | 254.615% |
| Poltreg S.A. | -2.91 PLN | -38.144% |
| Pure Biologics Spólka Akcyjna | -11.19 PLN | 64.075% |
| Synthaverse S.A. | 0.07 PLN | 6037.962% |
| Urteste S.A. | -4.32 PLN | 6.944% |